This post concludes our review of the meeting minutes of the MHRA’s Commission On Human Medicines (CHM) COVID-19 Vaccines Benefit Risk Expert Working Group (EWG), which took place until 15 February 2021.
We focused on the activity leading up to conditional market authorisation (CMA), which occurred in the UK at the end of 2020 and on the first day of t…